AR033360A1 - Formas cristalinas de (2s,3s,5s)-2-(2,6-dimetilfenoxiacetil)amin-3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanoil) amin-1,6-difenilhexano (lopinavir) - Google Patents
Formas cristalinas de (2s,3s,5s)-2-(2,6-dimetilfenoxiacetil)amin-3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanoil) amin-1,6-difenilhexano (lopinavir)Info
- Publication number
- AR033360A1 AR033360A1 ARP010101522A ARP010101522A AR033360A1 AR 033360 A1 AR033360 A1 AR 033360A1 AR P010101522 A ARP010101522 A AR P010101522A AR P010101522 A ARP010101522 A AR P010101522A AR 033360 A1 AR033360 A1 AR 033360A1
- Authority
- AR
- Argentina
- Prior art keywords
- amin
- lopinavir
- tetrahydropirimid
- methylbutanoil
- dimethylphenoxiacetile
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Formas cristalinas del compuesto (2S, 3S, 5S)-2-(2,6-dimetilfenoxiacetil) amin-3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanoíl)amin-1,6-difenoxihexano(lopinavir). Se describen las formas cristalinas hidratadas solvatadas, las formas cristalinas y las formas cristalinas no solvatadas de lopinavir así como las formas sustancialmente puras de todas las formas anteriormente mencionadas. El lopinavir es de utilidad en la inhibicion de la proteasa del VIH y la inhibicion de una infeccion por VIH.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53825700A | 2000-03-30 | 2000-03-30 | |
| US09/793,536 US6608198B2 (en) | 2000-03-30 | 2001-02-27 | Crystalline pharmaceutical |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR033360A1 true AR033360A1 (es) | 2003-12-17 |
Family
ID=27065762
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101522A AR033360A1 (es) | 2000-03-30 | 2001-03-29 | Formas cristalinas de (2s,3s,5s)-2-(2,6-dimetilfenoxiacetil)amin-3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanoil) amin-1,6-difenilhexano (lopinavir) |
| ARP050102702A AR049560A2 (es) | 2000-03-30 | 2005-06-29 | Formas cristalinas de (2s,3s,5s)-2-(2,6-dimetilfenoxiacetil) amin 3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanol)amin-1,6-difenilhexano (lopinavir) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102702A AR049560A2 (es) | 2000-03-30 | 2005-06-29 | Formas cristalinas de (2s,3s,5s)-2-(2,6-dimetilfenoxiacetil) amin 3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanol)amin-1,6-difenilhexano (lopinavir) |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1268442A2 (es) |
| JP (1) | JP2003529592A (es) |
| KR (1) | KR100773258B1 (es) |
| CN (2) | CN1330639C (es) |
| AR (2) | AR033360A1 (es) |
| AU (3) | AU5092001A (es) |
| BG (1) | BG107165A (es) |
| BR (1) | BR0109433A (es) |
| CA (1) | CA2403635A1 (es) |
| CZ (1) | CZ20023529A3 (es) |
| HU (1) | HUP0302675A3 (es) |
| IL (1) | IL151551A0 (es) |
| MX (1) | MXPA02009559A (es) |
| MY (1) | MY128296A (es) |
| NO (1) | NO325005B1 (es) |
| NZ (1) | NZ521183A (es) |
| PE (1) | PE20011232A1 (es) |
| PL (1) | PL359727A1 (es) |
| SA (2) | SA06270303B1 (es) |
| SK (1) | SK14832002A3 (es) |
| TW (1) | TWI284640B (es) |
| WO (1) | WO2001074787A2 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6608198B2 (en) | 2000-03-30 | 2003-08-19 | Abbott Laboratories | Crystalline pharmaceutical |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| ES2459301T3 (es) * | 2009-02-06 | 2014-05-08 | Hetero Research Foundation | Nuevos polimorfos de lopinavir |
| US8637449B2 (en) * | 2009-08-27 | 2014-01-28 | Merck Sharp & Dohme Corp. | Processes for preparing protease inhibitors of hepatitis C virus |
| CN112830899A (zh) * | 2021-01-18 | 2021-05-25 | 合肥华方医药科技有限公司 | 一种洛匹那韦新晶型及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5914332A (en) | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| WO1998057648A1 (en) * | 1997-06-16 | 1998-12-23 | Vertex Pharmaceuticals Incorporated | Methods of increasing the bioavailability of stable crystal polymorphs of a compound |
-
2001
- 2001-03-07 MY MYPI20011034A patent/MY128296A/en unknown
- 2001-03-21 IL IL15155101A patent/IL151551A0/xx unknown
- 2001-03-21 SK SK1483-2002A patent/SK14832002A3/sk not_active Application Discontinuation
- 2001-03-21 EP EP01924250A patent/EP1268442A2/en not_active Withdrawn
- 2001-03-21 HU HU0302675A patent/HUP0302675A3/hu unknown
- 2001-03-21 AU AU5092001A patent/AU5092001A/xx active Pending
- 2001-03-21 WO PCT/US2001/009112 patent/WO2001074787A2/en active IP Right Grant
- 2001-03-21 BR BR0109433-5A patent/BR0109433A/pt not_active Application Discontinuation
- 2001-03-21 CN CNB018076882A patent/CN1330639C/zh not_active Expired - Lifetime
- 2001-03-21 NZ NZ521183A patent/NZ521183A/en not_active IP Right Cessation
- 2001-03-21 KR KR1020027012849A patent/KR100773258B1/ko active IP Right Grant
- 2001-03-21 CA CA002403635A patent/CA2403635A1/en not_active Abandoned
- 2001-03-21 CZ CZ20023529A patent/CZ20023529A3/cs unknown
- 2001-03-21 AU AU2001250920A patent/AU2001250920B2/en not_active Revoked
- 2001-03-21 JP JP2001572482A patent/JP2003529592A/ja active Pending
- 2001-03-21 MX MXPA02009559A patent/MXPA02009559A/es active IP Right Grant
- 2001-03-21 CN CNA2007101123988A patent/CN101066952A/zh active Pending
- 2001-03-21 PL PL35972701A patent/PL359727A1/xx not_active Application Discontinuation
- 2001-03-29 AR ARP010101522A patent/AR033360A1/es not_active Application Discontinuation
- 2001-03-30 PE PE2001000299A patent/PE20011232A1/es not_active Application Discontinuation
- 2001-05-02 TW TW090107717A patent/TWI284640B/zh active
- 2001-08-07 SA SA06270303A patent/SA06270303B1/ar unknown
- 2001-08-07 SA SA01220270A patent/SA01220270B1/ar unknown
-
2002
- 2002-09-30 NO NO20024679A patent/NO325005B1/no not_active Application Discontinuation
- 2002-10-03 BG BG107165A patent/BG107165A/bg unknown
-
2005
- 2005-06-29 AR ARP050102702A patent/AR049560A2/es unknown
-
2006
- 2006-09-27 AU AU2006222711A patent/AU2006222711A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR049560A2 (es) | 2006-08-16 |
| CN101066952A (zh) | 2007-11-07 |
| CZ20023529A3 (cs) | 2003-02-12 |
| BR0109433A (pt) | 2004-08-10 |
| NO20024679L (no) | 2002-09-30 |
| SA01220270B1 (ar) | 2006-11-14 |
| HUP0302675A3 (en) | 2004-03-29 |
| TWI284640B (en) | 2007-08-01 |
| NZ521183A (en) | 2004-03-26 |
| WO2001074787A2 (en) | 2001-10-11 |
| CA2403635A1 (en) | 2001-10-11 |
| PE20011232A1 (es) | 2001-12-08 |
| MY128296A (en) | 2007-01-31 |
| AU2006222711A1 (en) | 2006-10-19 |
| NO325005B1 (no) | 2008-01-14 |
| WO2001074787A3 (en) | 2002-02-07 |
| SA06270303B1 (ar) | 2009-08-02 |
| JP2003529592A (ja) | 2003-10-07 |
| IL151551A0 (en) | 2003-04-10 |
| MXPA02009559A (es) | 2003-05-21 |
| CN1422259A (zh) | 2003-06-04 |
| CN1330639C (zh) | 2007-08-08 |
| AU2001250920B2 (en) | 2006-06-29 |
| KR20030011807A (ko) | 2003-02-11 |
| EP1268442A2 (en) | 2003-01-02 |
| NO20024679D0 (no) | 2002-09-30 |
| PL359727A1 (en) | 2004-09-06 |
| KR100773258B1 (ko) | 2007-11-05 |
| BG107165A (bg) | 2003-07-31 |
| AU5092001A (en) | 2001-10-15 |
| SK14832002A3 (sk) | 2003-02-04 |
| HUP0302675A2 (hu) | 2003-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60315023D1 (de) | Anreicherung in der zelle an phosphonat analoga von hiv protease inhibitor verbindungen und die verbindungen selbst | |
| ATE445400T1 (de) | Hydantion-derivate als hemmer von matrix- metalloproteinasen | |
| ES2177868T3 (es) | Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas. | |
| CY1110690T1 (el) | Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv | |
| MY142948A (en) | Benzophenones as inhibitors of reverse transcriptase | |
| ATE373005T1 (de) | Thienopyrrole als antivirale mittel | |
| CO5540347A2 (es) | Derivados de dipeptido que contiene un grupo 2-tioacilo n-terminal como inhibidores de vasopeptidasa | |
| ECSP056181A (es) | Compuestos Inhibidores de la Hepatitis C | |
| AR049560A2 (es) | Formas cristalinas de (2s,3s,5s)-2-(2,6-dimetilfenoxiacetil) amin 3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanol)amin-1,6-difenilhexano (lopinavir) | |
| DE60221508D1 (de) | Aminosäurederivate als hiv-protease-inhibitoren | |
| EA200701692A1 (ru) | Ингибиторы протеазы вич | |
| ATE499837T1 (de) | Antimikrobielle zusammensetzungen, die ethanolamid-puffer und biguanid- desinfektionsmittel enthalten | |
| BR0112655A (pt) | Derivados de pirrolidino como inibidores de metaloproteases | |
| PE74799A1 (es) | Combinaciones antivirales | |
| DK0666755T3 (da) | Inhibering af HIV-infektion | |
| AR013087A1 (es) | Forma v de amprenavir, su uso como compuesto antiviral, un proceso para prepararlo, y composiciones farmaceuticas que lo comprenden | |
| UY27448A1 (es) | Ésteres de análogos de 3-desoxi-vitamina d3 | |
| UY27033A1 (es) | Nuevos compuestos para su uso como inhibidores de la proteasa de vih | |
| IT1318424B1 (it) | Composti con attivita' anti-hiv. | |
| SE9902271D0 (sv) | Pharmaceutically active compounds | |
| AU7076600A (en) | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase | |
| DE602005010869D1 (de) | Peptidomimetische hemmer von hiv-protease | |
| TH22511A (th) | Use of quinoxalines in combination with protease inhibitors as medicaments for treation, aids and/or hiv infections | |
| ECSP003509A (es) | Inhibidores de metaloproteasas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |